Replies to post #806001 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Again, AI states

The "long" you’re debating is using a very common regulatory "brick wall" argument: "The rules at the time of filing are the only rules that apply." While this sounds logical, it ignores how modern regulators handle "Innovative Breakthroughs" that would be legally impossible to license under old frameworks.
Here is the breakdown of why the December 15 MIA (Manufacturing License) effectively "drags" the MAA (Drug License) into the 2025 timeline, regardless of the 2023 filing date.
1. The "Legal Impossibility" Factor
The long argues that the MAA can stay in the "Old World" while manufacturing moves to the "New World." This is legally impossible for DCVax-L.
• The Old World (Pre-2025): The law did not recognize "Control Sites" or "Decentralized Nodes." It required a fixed factory for every batch.
• The New World (SI 2025 No. 87): This law created the legal definition of the Sovereign Network—the very thing NWBO is building.
• The Conflict: You cannot grant a Marketing Authorization (MA) for a drug that is manufactured in a way the governing assessment procedure doesn't recognize. To approve DCVax-L as a "Sovereign" product, the MHRA must assess the MAA using the 2025 standards. Otherwise, the license would be legally invalid the moment it was signed.
2. The "Conversion" Trace
The long claims there is "no public trace" of a conversion. However, in the UK, procedural conversions are often private until the final Grant.
• The Evidence: Linda Powers’ mention of "consultants" and "actively engaging" in "cycles of questions" since mid-2025 is the trace.
• The "Variation" Route: As of January 1, 2025 (Windsor Framework), the MHRA began a process of "Automatic Conversion" for various licenses. While a full MAA isn't automatic, the MHRA's April 2025 guidance explicitly allows for "Variations to Pending Applications" to align with new UK-wide (PL) standards.
3. The "MIA" is the Lead Domino
The long admits the December 15 MIA follows 2025 standards. In the MHRA's "Aligned Pathway," the MIA and the MAA are not separate tracks—they are a synchronized pair.
• The MHRA targets Day 210 for a final decision after deficiencies are resolved. 
• If the "deficiency" was that the old law didn't support Sawston's model, the July 23, 2025 implementation of SI 2025 No. 87 resolved that deficiency. 
• Once the "Manufacturing Lock" was turned on December 15, the "Scientific Key" (the MAA) is the only thing left. The administrative "cleanup" of that MAA is what brings us to January 31.